Advances in imaging evaluation of neoadjuvant chemotherapy efficacy of triple negative breast cancer

ZHU Can; SHEN Yan-yan

Journal of China Clinic Medical Imaging ›› 2016, Vol. 27 ›› Issue (12) : 904-906.

ZHU Can, SHEN Yan-yan

Author information +

History +

Abstract

Triple negative breast cancer(TNBC) is highly invasive. It is not sensitive to endocrine therapy, but has a good response to neoadjuvant chemotherapy. So NAC has become an important part of the comprehensive treatment of TNBC. The imaging evaluation of neoadjuvant chemotherapy is very important for early clinical treatment options, including mammography, ultrasound, MRI, PET-CT, etc. This article will provide an overview of these techniques used to evaluate the efficacy of neoadjuvant chemotherapy for TNBC.

Key words

Breast neoplasms / Radiography / Ultrasonography, mammary / Magnetic resonance imgaing / Positron-emission tomography

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHU Can, SHEN Yan-yan. Advances in imaging evaluation of neoadjuvant chemotherapy efficacy of triple negative breast cancer[J]. Journal of China Clinic Medical Imaging. 2016, 27(12): 904-906

References

[1]Navrátil J, Fabian P, Palácová M, et al. Triple negative breast cancer[J]. Klin Onkol, 2015, 28(6): 405-415.
[2]Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer[J]. Surg Clin North Am, 2013, 93(2): 493-499.
[3]Von MG, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(30): 1796-1804.
[4]Weiss A, Lee KC, Romero Y, et al. Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2014, 21(10): 3310-3316.
[5]Adrada BE, Huo L, Lane DL, et al. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer[J]. Ann Surg Oncol, 2015, 22(4): 1111-1117.
[6]Golan O, Amitai Y, Menes T. Does change in microcalcifications with neoadjuvant treatment correlate with pathological tumour response?[J]. Clin Radiol, 2016, 71(5): 458-463.
[7]Atkins JJ, Appleton CM, Fisher CS, et al. Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?[J]. Oncol, 2013, 2013: 964863.
[8]李妙珊，冯占武，刘娟娟，等. 超声评价三阴性乳腺癌新辅助化疗疗效的价值[J]. 中国超声医学杂志，2015，31（12）：1067-1070.
[9]周如海，邬颖杰，吴猛，等. 超声造影技术在乳腺癌新辅助化疗疗效评估中的应用价值[J]. 医学影像学杂志，2015，25（4）：711-714.
[10]Amioka A, Masumoto N, Gouda N, et al. Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy[J]. Jpn J Clin Oncol, 2016, 46(4): 303-309.
[11]Cao X, Xue J, Zhao B. Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer[J]. Ultrasound Med Biol, 2012, 38(12): 2065-2071.
[12]Sannachi L, Tadayyon H, Sadeghi-Naini A, et al. Non-invasive evaluation of breast cancer response to chemotherapy using quantitative ultrasonic backscatter parameters[J]. Med Image Anal, 2014, 20(1): 224-236.
[13]Tadayyon H, Sannachi L, Gangeh M, et al. Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach[J]. Oncotarget, 2016. [Epub ahead of print]
[14]Nakahara H, Yasuda Y, Machida E, et al. MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes[J]. Breast Cancer, 2011, 18(3): 152-160.
[15]Moon HG, Han W, Ahn SK, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy[J]. Ann Surg, 2013, 257(1): 133-137.
[16]Kawashima H, Inokuchi M, Furukawa H, et al. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects[J]. Springerplus, 2014, 3: 240.
[17]Choi JS, Ko ES, Ko EY, et al. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy[J]. Medicine (Baltimore), 2016, 95(9): e3000.
[18]Drisis S, Metens T, Ignatiadis M, et al. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy[J]. Eur Radiol, 2016, 26(5): 1474-1484.
[19]Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology[J]. J Clin Oncol, 2007, 25(26): 4104-4109.
[20]Liu S, Ren R, Chen Z, et al. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy[J]. J Magn Reson Imaging, 2015, 42(3): 779-787.
[21]Belli P, Costantini M, Malaspina C, et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy[J]. Clin Radiol, 2006, 61(11): 946-953.
[22]Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy[J]. AJR, 2003, 181(5): 1275-1282.
[23]Koolen BB, Pengel KE, Wesseling J, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 32-40.
[24]Koolen BB, Pengel KE, Wesseling J, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer[J]. Breast, 2013, 22(5): 691-697.